Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: placebo
Drug: liraglutide

First Posted Date: 2013-04-22

Last Posted Date: 2017-03-06

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1398

Registration Number: NCT01836523

Locations: 🇬🇧
Novo Nordisk Investigational Site, Stevenage, United Kingdom

A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin degludec/insulin aspart
Drug: insulin detemir
Drug: insulin aspart

First Posted Date: 2013-04-19

Last Posted Date: 2019-06-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 362

Registration Number: NCT01835431

Locations: 🇪🇸
Novo Nordisk Investigational Site, Madrid, Spain

Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: Faster-acting insulin aspart
Drug: insulin aspart
Drug: insulin detemir

First Posted Date: 2013-04-15

Last Posted Date: 2019-06-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1290

Registration Number: NCT01831765

Locations: 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom

A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors

Completed

Conditions: Haemophilia A With Inhibitors
Haemophilia B With Inhibitors
Congenital Bleeding Disorder

Interventions: Drug: eptacog alfa (activated)

First Posted Date: 2013-04-12

Last Posted Date: 2023-12-29

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 15

Registration Number: NCT01830712

Locations: 🇺🇸
Novo Nordisk Clinical Trial Call Center, Princeton, New Jersey, United States

Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: liraglutide

First Posted Date: 2013-04-01

Last Posted Date: 2017-08-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 64

Registration Number: NCT01821846

Locations: 🇰🇷
Novo Nordisk Investigational Site, Wonju, Korea, Republic of

Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: Faster-acting insulin aspart
Drug: Insulin aspart
Drug: Insulin glargine

First Posted Date: 2013-03-27

Last Posted Date: 2019-01-30

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 881

Registration Number: NCT01819129

Locations: 🇬🇧
Novo Nordisk Investigational Site, Wrexham, United Kingdom

A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin degludec/insulin aspart
Drug: insulin degludec
Drug: insulin aspart

First Posted Date: 2013-03-19

Last Posted Date: 2017-03-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 40

Registration Number: NCT01814137

Locations: 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey

A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0287 in Healthy Subjects

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin 287
Drug: insulin glargine
Drug: placebo

First Posted Date: 2013-03-12

Last Posted Date: 2017-03-01

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 84

Registration Number: NCT01809184

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in Subjects With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin 338 (GIPET I)
Drug: insulin glargine
Drug: placebo

First Posted Date: 2013-02-21

Last Posted Date: 2017-03-01

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 40

Registration Number: NCT01796366

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

A Trial Investigating the Effect of Acute Hypoglycaemia on Cognitive Function and Brain Activation Patterns in Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes

Interventions: Other: glucose clamp

First Posted Date: 2013-02-12

Last Posted Date: 2018-01-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 29

Registration Number: NCT01789593

Locations: 🇩🇰
Novo Nordisk Investigational Site, Århus C, Denmark

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy